Skip to content
DataLookout
Menu

NCT07042295

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 103 versions: 28 with changes below, 22 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 57 → 60 locations
  2. Minor Study sites: 58 to 59
  3. Minor Trial sites expanded: 54 → 57 locations
  4. Minor Study sites: 55 to 57
  5. Minor Site details revised at 1 of 55 sites
  6. Minor Study sites: 54 to 55
  7. Notable Recruitment resumed after suspension Show 4 more changesShow less
    • Eligibility criteria expanded, about 54 words
    • Trial sites expanded: 51 → 54 locations
    • Secondary endpoints: details revised at 1 of 6 entries
    • Study description revised
  8. Stopped Recruitment suspended Sponsor's reason: Other - planned analysis of safety and efficacy data
    • Site details revised at 51 of 51 sites
    v96
  9. Minor Trial sites expanded: 42 → 50 locationsv95
  10. Minor Study sites: 42 to 50v94
  11. Minor Study sites: 41 to 42v93
  12. Minor Trial sites expanded: 38 → 41 locationsv92
  13. Minor Study sites revised (38)v91
  14. Notable Eligibility criteria expanded, about 6 words
    • Study description shortened, about 3 words
    v90
  15. Notable Trial status: Suspended to Recruiting
    • Study sites: 32 to 38
    v89
  16. Minor Study sites revised (32)v87
  17. Stopped Recruitment suspended Sponsor's reason: Other - safety run-in for initial cohort of participants
    • Site details revised at 32 of 32 sites
    v85
  18. Minor Study sites: 31 to 32v84
  19. Minor Study sites: 30 to 31v82
  20. Minor Study sites: 29 to 30v81
  21. Minor Study sites: 27 to 29v80
  22. Minor Trial sites expanded: 20 → 23 locationsv79
  23. Minor Trial sites expanded: 17 → 20 locationsv78
  24. Minor Study sites: 20 to 23v77
  25. Minor Study sites: 17 to 20v76
  26. Minor Trial sites expanded: 9 → 17 locationsv67
  27. Minor Start date changed from estimate of Oct 25, 2026 to Mar 23, 2026v64
  28. Minor Study sites: 8 to 9v59
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of toxicity of interest (cohort A)
Timeframe: Up to completion of the first cycle (cycle length = 28 days)
Progression free survival (PFS) (cohort B)
Timeframe: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, up to 3 years

Secondary (6)

Organ rejection
Overall survival (OS)
PFS
Time to next treatment
Time to progression
Show 1 moreShow less
Duration of objective response

Arms and interventions

Arm I (amivantamab and hyaluronidase)Experimental

Patients receive amivantamab and hyaluronidase SC over at least 5 minutes on days 1, 8, 15 and 22 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study and CT scan and/or MRI throughout the study.

Arm II (cetuximab)Active comparator

Patients receive cetuximab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection on study and CT and/or MRI throughout the study.

Drugs: Amivantamab and Recombinant Human Hyaluronidase

Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging

Biologicals: Cetuximab

Sites

60 sites in 1 country